Role of endothelial dysfunction and intestinal microbiota in the development metabolic syndrome
https://doi.org/10.24884/1609-2201-2024-103-3-81-89
Abstract
In the article the data is about the pathogenesis of endothelial dysfunction in metabolic syndrome. The clinical picture and pathogenic particularities are described. According to recent studies the role of gut microbiota in the development of metabolic syndrome is not in doubt. Specific bacteria species can be considered as predictors of the metabolic syndrome presence.
About the Author
A. N. Shishkin
Saint-Petersburg State University
Russian Federation
Russian Federation
Alexandr N. Shishkin, Dr. of Sci. (Med.), Professor, Head of the Department of Faculty Therapy
/9 Universitetskaya Emb., Saint Petersburg, 199034
References
1. Stroyev Yu. L, Tsoy M. V., Churilov L. P., Shishk’in A. N. Classicand Modern Conceptsofthe Metabolic Syndrome. Part 1. Criteria, Epidemiology, Etiology. Vestnik of Saint Petersburg University. 2007;11(1):13–16. (In Russ.).
2. Nolan P. B., Carrick-Ranson G., Stinear J. W. et al. Prevalence of metabolic syndrome and metabolic syndrome components in young adults: A pooled analysis. Preventive Medicine Reports. 2017;7:211–215.
3. Lemieux I., Pascot A., Couillard C. et.al. Hypertriglyceridemic waist: a marker of the atherogenicmetabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102:179–184.
4. Dunstan D. W., Zimmet P. Z., Welborn T. A. et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25:829–34.
5. Proença I. M., Allegretti J. R., Bernardo W. M. et al. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. Nutrition Research. 2020;83:1–14.
6. Dedov I. I., Mokrysheva N. G., Mel’nichenko G. A. et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311–325. (In Russ.). https://doi.org/10.26442/20751753.2021.4.200832.
7. International Diabetes Federation. Promoting diabetes care, prevention and cure worldwide. Backgrounder I. The IDP consensus worldwide definition of the metabolic syndrome:1–7. [7 screens, 2 June 2005]. URL: http://www.saegre.org.ar/biblioteca/arbol_bibliografico/junio2005/IDF_Metasyndrome_definition.pdf (accessed: 20.08.24).
8. Shishkin A. N. Modern strategy of therapy of endothelial dysfunction from the position of evidence-based medicine. Novye St. Petersburgskie Vrachebnye Vedomosti. 2008;3:16–19. (In Russ.).
9. Zaichik A. Sh., Churilov L. P., Stroev Y. I. The concept of metabolic syndrome. Pathophysiology. Vol. II. Pathochemistry. Pathophysiology of the endocrine system and metabolism. 3rd ed. St. Petersburg, 2007. (In Russ.).
10. Ivanova O. V., Soboleva G. N., Karpov Y. A. Endothelial dysfunction – an important stage in the development of atherosclerotic vascular lesions (literature review – 1) Ter. Archiv. 1997;6:75–78. (In Russ.).
11. Adams M. R., Robinson J., McCredie R. et al. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J. Am. Coll. Cardiol. 1998;32(1):123–127.
12. Cai H., Harrison D. G. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ. Res. 2000;87:840–844.
13. Roitberg G. E. Metabolic syndrome / eds by corr. member of RAMS G. E. Roitberg. М., MED-press-inform, 2007. 224 p. (In Russ.).
14. Panina I. Yu., Rumyantsev A. Sh., Menshutina M. A. et al. Features of endothelial function in chronic kidney disease. Literature review and own data. Nephrology. 2007;11(4):28–42. (In Russ.).
15. Petrishchev N. N, Vlasov T. D. Physiology and pathophysiology of endothelium. Endothelial dysfunction. Causes, mechanisms, pharmacologic correction / eds by N. N. Petrishchev. St. Petersburg, Publishing house of St. Petersburg State Medical University, 2003. P. 4–38. (In Russ.).
16. Britten M. B., Zeiher A. M., Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med. 1999;245(4):315–321.
17. Shishkin A. N., Kniazeva A. I. Endothelial dysfunction in patients with obesity. Regional Blood Circulation and Microcirculation. 2022;21(3):4–11. (In Russ.). https://doi.org/10.24884/16826655-2022-21-3-4-11.
18. Noguera A., Busquets X., Sauleda J. et al. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic pulmonary disease. Am J Crit Care Med. 1998;158(5):1664– 1668.
19. Marie I., Beny J. L. Endothelial dysfunction in murine model of systemic sclerosis. J Invest Dermatol. 2002;119(6):1379–1385.
20. Reutov V. P., Sorokina E. G., Kositzyn N. S. Problems of nitric oxide and cyclic recurrence in biology and medicine. Adv. Current Biol. 2005;(1):41–65). (In Russ.).
21. Bruno R. M., Reesink K. D., Ghiadoni L. Advances in the non-invasive assessment of vascular dysfunction in metabolic syndrome and diabetes: Focus on endothelium, carotid mechanics and renal vessels. Nutrition, Metabolism and Cardiovascular Diseases. 2017;(27):121–128. https://doi.org/10.1016/j.numecd.2016.09.004.
22. Endothelial dysfunction. Causes, mechanisms, pharmacological correction / eds by N. N. Petrischev. SPb, 2003. P. 4–39. (In Russ.).
23. Paloshi A., Fragasso G., Piatti P. et al. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol. 2004;93(7):933–935.
24. Shestakova M. V. Endothelial dysfunction – cause or consequence of metabolic syndrome? RMZH. 2001;9(2):88. (In Russ.).
25. Lippincott M. F., Carlow A., Desai A. et al. Relation of endothelial function to cardiovascular risk in women with sedentary occupations and without known cardiovascular disease. The Am Coll of Cardiol. 2008;102(iss.3):348–52.
26. Li T. Y., Rana J. S., Manson J. E. et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation. 2006;113:499–506.
27. Suzuki T., Hirata K., Elkind M. S. V. et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the northern Manhattan study (NOMAS). Am Heart J. 2008;156:405–410.
28. Zhao S., Kusminski C. M., Scherer P. E. Adiponectin, leptin and cardiovascular disorders. Circ Res. 2021;128(1):136–149. https://doi.org/10.1161/circresaha.120.314458.
29. American Diabetes Association: Standards of medical care in diabetes – 2008. Diabetes Care. 2008;31(Suppl. I):S12–S54.
30. Li T. Y., Rana J. S., Manson J. E. et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation. 2006;113:499–506.
31. Ravera M., Ratto E., Vettoretti S. et al. Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. J Nephrol. 2002;15:519–524.
32. Bianchi S., Bigazzi R., Campese V. M. Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999;34:973–995.
33. Van den Beld A. W., Bots M. L., Janssen J. A. et al. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157:25–31.
34. Jassal S.K., Langenberg C., von Muhlen D., Bergstrom J., Barrett-Connor E. Usefulness of microalbuminuria versus the metabolic syndrome as a predictor of cardiovascular disease in women and men > 40 years of age (from the Rancho Bernardo Study). Am J Cardiol. 2008;101:1275–1280.
35. Karalliedde J., Viberti G. Microalbuminuria and cardiovascular risk. Am J Hipertens. 2004;17:986–93.
36. Grinevich V. B., Zakharchenko M. M. Modern ideas about the importance of human intestinal microbiocenosis and ways of correction of its disorders. Novye Sankt-Petersburgskie Vrachebnye Vedomosti. 2003;(3):13–20. (In Russ.).
37. Cani P. D., Delzenne N. M. The Role of the Gut Microbiota in Energy Metabolism. Current Pharmaceutical Design. 2009;15(13):1546–1558.
38. Tilg H., Moschen A.R., Kaser A. Obesity and the Microbiota. Gastroenterology. 2009;136(Iss.5):1476–1483.
39. Tsukumo D. M., Carvalho B. M., Carvalho-Filho M. A., Saad M. J. Translational research into gut microbiota:new horizons in obesity treatment. Arq Bras Endocrinol Metabol. 2009;53(2):139–144.
40. Hugon, P., Lagier, J. C., Colson P. et al. Repertoire of human gut microbes. Microb. Pathog. 2017;106:103–112.
41. Callaway E. Microbiome privacy risk. Nature. 2015;521:136.
42. Yatsunenko T., Rey F. E., Manary M. J. et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222– 227.
43. Zhao S., Kusminski C. M., Scherer P. E. Adiponectin, leptin and cardiovascular disorders. Circ Res. 2021;128(1):136–149. https://doi.org/10.1161/circresaha.120.314458.
44. Eckburg P. B., Bik E. M., Bernstein C. N. et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635–1638.
45. Tap J., Mondot S., Levenez F. et al. Towards the human intestinal microbiota phylogenetic core. Environ. Microbiol. 2009;11(11):2574–2584.
46. Simbirtsev A. S., Gromov A. Y. Functional polymorphism gene regulatory cytokines. Cytokines and Inflammation. 2005;4(1):310–318.
47. Pircalabioru G. G., Ilie I., Oprea L. et al. Microbiome, mycobiome and related metabolites alterations in patients with metabolic syndrome – a pilot study. Metabolites. 2022;12(3):218. https://doi.org/10.3390/metabo12030218.
48. Ley R. E., Backhed F., Turnbaugh P. et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA. 2005;102(31):11070–11075.
49. Ley R. E., Turnbaugh P. J., Klein S., Gordon J. I. Human gut microbes associated with obesity. Nature. 2006;444(7122):1022–1023.
50. Chávez-Carbajal A., Nirmalkar K., Pérez-Lizaur A. et al. Gut microbiota and predicted metabolic pathways in a sample of mexican women affected by obesity and obesity plus metabolic syndrome. Int. J. Mol. Sci. 2019;20:438.
51. Magne F., Gotteland M., Gauthier L. et al. The firmicutes/bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients? Nutrients. 2020;12(5):1474.
52. Schwiertz A., Taras D., Schafer K. et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18:190–195.
53. Santacruz A., Collado M. C., García-Valdés L. et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr. 2010;104(1):83–92.
54. Fei N., Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. The ISME Journal. 2013;7(4):880–884.
55. Remely M., Hippe B., Geretschlaeger I. et al. Increased gut microbiota diversity and abundance of Faecalibacterium prausnitzii and Akkermansia after fasting: a pilot study. Wien Klin Wochenschr. 2015;127(9–10):394–398.
56. Zupancic M. L., Cantarel B. L., Liu Z. et al. Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. PLoS One. 2012;7(8):e43052.
57. Verdam F. J., Fuentes S., de Jonge C. et al. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity (Silver Spring). 2013;21(12):607–615.
58. Ivashkin V. T., Medvedev O. S., Poluektova E. A. et al. Direct and indirect methods of studying human microbiota. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;2(32):19–34. (In Russ.)
Review
For citations:
Shishkin A.N. Role of endothelial dysfunction and intestinal microbiota in the development metabolic syndrome. New St. Petersburg Medical Records. 2024;(3):81-89. (In Russ.) https://doi.org/10.24884/1609-2201-2024-103-3-81-89
Views:
77
Email this article 